To view the publications, please select the year of publication first followed by clicking on the (+) sign to access the full list of publications for that year. When you are ready to view the publications for another year, please click on the (-) sign to return to the initial default display.
Publications: 2000
|
Nabholtz J, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, Von Euler M. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. J Clin Oncol 18: 3758-67, 2000. |
|
|
Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone IGF Res 10 Suppl B: 21-4, 2000. |
|
|
Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60: 5617-20, 2000. |
|
|
Byrne C, Colditz G, Willett W, Speizer F, Pollak M, Hankinson S. Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein 3, and mammographic Density. Cancer Res 60: 3744-8, 2000. |
|
|
Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal C. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 267: 4020-7, 2000. |
|
|
Platz EA, Pollak MN, Willett W, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol 42: 1003-7, 2000. |
|
|
Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000. |
|
|
Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-9, 2000. |
|
|
Foulkes WD, Chappuis PO, Wong N, Brunet J, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 3: 307-13, 2000. |
|
|
Miyake H, Pollak M, Gleave M. Castration-induced upregulation of IGFBP-5 potentiates IGF-I activity and accelerates progression to androgen-independence in prostate cancer models. Cancer Res 60: 3058-64, 2000. |
|
|
Huynh H, Beamer W, Pollak M, Chan T. Modulation of transforming growth factor beta 1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16: 277-81, 2000. |
Publications: 1999
|
Platz E, Pollak M, Rimm E, Majeed N, Tao Y, Willett W, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8: 1107-10, 1999. |
|
|
Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased gene expression of insulin-like growth factor binding proteins. Urology 54: 1120-5, 1999. |
|
|
Buhlmann C, Borchers T, Pollak M, and Spener F. Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Mol Cell Biochem 199: 41-8, 1999. |
|
|
Rozen F, Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol. 15: 589-94, 1999. |
|
|
Nickerson T, Miyake H, Gleave M, and Pollak M Castration-induced apoptosis of androgen-dependent Shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins. Cancer Res 59: 3392-5, 1999. |
|
|
Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Int J Oncol 14: 987-90, 1999. |
|
|
Rosen C and Pollak M. Circulating IGF-I: a new perspective for a new century. Trends Endocrinol Metab 10: 136-41, 1999. |
|
|
Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Rev 17: 383-90, 1998-1999. |
|
|
Pollak M, Beamer W, Zhang J. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17: 383-90, 1999. |
|
|
Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. J Natl Cancer Inst 91: 620-5, 1999 |
|
|
Ingle J, Suman V, Kardinal C, Krook J, Mailliard J, Veeder M, Loprinzi C, Dalton R, Hartmann L, Conover C, Pollak M. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85: 1284-92, 1999. |
Publications: 1998
|
Burrow S, Andrulis I, Pollak M, Bell R. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-7, 1998. |
|
|
Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13: 865-9, 1998. |
|
|
Huynh H, Pollak M, Zhang J. Regulation of IGF-II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB 1089. Int J Oncol 13: 137-143, 1998. |
|
|
Pollak M. Effects of anti-estrogens on insulin-like growth factor-I physiology systemically and in the uterus. Eur J Cancer 34 (Supp 4) S1-S8, 1998. |
|
|
Hankinson S, Willett W, Colditz G, Hunter D, Michaud D, Deroo B, Rosner B, Speizer F, Pollak M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393-96, 1998. [see also favorable editorial comment [.pdf] : Lancet 351: 1373-4, 1998] |
|
|
Pollak M. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-17, 1998. |
|
|
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens C, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998 [see also favorable editorial comment [.pdf] - Science 279: 475, 1998] |
|
|
Pollak M, Schally A. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc for Exp Biol Med 217: 143-52, 1998. |
|
|
Nickerson T, Pollak M,Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding IGF binding proteins 2,3,4, and 5. Endocrinology 139: 807-810, 1998. |